MEDP · Medpace Holdings, Inc.

Current Thesis

Medpace's bookings recovery supports a renewed test of its market high; a weekly close above $620.75 would confirm the price leg, while a weekly close below $578 would invalidate it. The fundamental test remains the next quarterly report: whether net new awards sustain the 1.13x book-to-bill ratio reported on 2026-07-22 and management maintains its raised revenue guidance. Book-to-bill measures new business awards relative to reported revenue.

The September refresh changes both the price and insider-supply readings. The adjusted close recovered from $591.29 on 2026-09-04 to $612.33 on 2026-09-18. Separately, the chief executive's Form 4 filed on 2026-09-17 records renewed sales, ending the previously observed pause. September 17 Form 4

The life-cycle assessment is an inference: the narrative is maturing — the 2026-09-18 recovery toward the high weakens the September 6 saturation assessment, but the latest operating release remains dated 2026-07-22. This is a recovery in price without a new quarterly bookings observation; it does not establish expanding investor participation. Company releases

Bullish and bearish views on Medpace Holdings, Inc.

The model's bull view on Medpace Holdings, Inc. (MEDP), in brief: Awards support the operating thesis. Medpace reported second-quarter net new business awards of $795.7 million, up 28.2% year over year, and book-to-bill of 1.13x on 2026-07-22. These are measured results; the sample is too small to establish a durable acceleration. Source… The bear view: Insider supply has resumed. Chief executive August J. The filing says these transactions followed a limit order placed during an open trading window; it establishes selling, without establishing the executive's outlook. September 17 Form 4 Attention is not measured demand. The… Both cases follow in full.

Bull Case

• Awards support the operating thesis. Medpace reported second-quarter net new business awards of $795.7 million, up 28.2% year over year, and book-to-bill of 1.13x on 2026-07-22. These are measured results; the sample is too small to establish a durable acceleration. Source: Medpace second-quarter results and the dated Benzinga awards report.
• Guidance raised the revenue hurdle. On 2026-07-22, management raised its fiscal 2026 revenue forecast to $2.805–2.885 billion and its earnings-per-share forecast under generally accepted accounting principles to $17.25–17.95. Maintaining those ranges at the next report is a condition of the operating case, rather than an assumed outcome. Source: Medpace's July 22 guidance update.
• Price has recovered toward resistance. The supplied adjusted market series places the 2026-09-18 close at $612.33, 1.4% below its $620.75 52-week high, with a three-month price increase of 34.4%. The price leg remains unconfirmed until a weekly close exceeds that high.

Bear Case

• Insider supply has resumed. Chief executive August J. The filing says these transactions followed a limit order placed during an open trading window; it establishes selling, without establishing the executive's outlook. September 17 Form 4
• Attention is not measured demand. The supplied news record contains a Benzinga retrospective dated 2026-09-11 about historical shareholder returns. That observation alone is too small a sample to support a claim of retail crowding, and it supplies no new operating result.
• Operating confirmation remains outstanding. As checked on 2026-09-20, the company's events page lists no upcoming event and its releases page still ends with the 2026-07-22 results. The recovery therefore lacks a subsequent company-reported bookings observation. Events, releases

Setup & Price Structure

The 2026-09-18 adjusted close of $612.33 sits below the supplied $620.75 market high. The 14-day relative strength index was 57.0 on that date. A moving-average value, turnover series and short-interest observation are missing, so neither distance above a rising average nor a squeeze claim is supported.

The research boundary remains the $578 pullback level identified with 2026-08-14 in the September 6 published analysis. A weekly close below $578 would break that structure; a weekly close above $620.75 before that breach would complete the defined price case. The evidence supports medium conviction: the September 18 recovery improves the structure, while the September 17 insider filing and absence of a new operating report limit confirmation.

Catalyst Calendar (next 30 days)

• 2026-09-20 through 2026-10-20: No company-confirmed earnings or investor-event date appears on Medpace's events page as checked on 2026-09-20. A scheduling announcement has no verified date and is not treated as a scheduled catalyst. Company calendar
• ~2026-10-28, est., beyond the window: MarketBeat estimates this date for third-quarter earnings and explicitly says Medpace has not confirmed it. The report provides the next test of bookings and revenue guidance; the date remains provisional until a company announcement supersedes it. MarketBeat earnings calendar

What Would Change Our Mind

Loss of the August pullback structure would end the price thesis: a weekly close below $578 is the observable boundary. Separately, third-quarter net book-to-bill below 1.10x would fail the operating threshold specified in the September 6 research, while a reduction to the fiscal 2026 revenue range announced on 2026-07-22 would undermine the expected conversion of awards into revenue. The 1.10x threshold is an analytical condition, not company guidance.

Confirmation requires distinct observations. A weekly close above the supplied September 18 market high of $620.75 completes the price leg; third-quarter book-to-bill at or above the July 22 reported 1.13x, alongside maintained revenue guidance, confirms the operating case. A price breakout alone cannot establish that award growth persisted.

Correlation Notes

This remains a single-company setup anchored in Medpace's 2026-07-22 awards and guidance. Its contract research organization business provides clinical-development services, making Picks & Shovels the relevant profile rather than a thesis dependent on one drug approval. Company description

The 2026-09-18 evidence contains no matched return series for Medpace, ICON or the SPDR S&P Biotech ETF. It therefore supports no measured correlation, diversification claim or attribution of Medpace's recovery to a broader biotechnology move.